•
Dec 31, 2020
Cassava Sciences Q4 2020 Earnings Report
Announced full-year financial results and provided business highlights.
Key Takeaways
Cassava Sciences reported a net loss of $6.3 million for the full year 2020, with cash and cash equivalents at $93.5 million as of December 31, 2020. The company is on track to initiate two pivotal Phase 3 studies in the second half of 2021 and expects net cash use of $20 to $25 million in 2021.
Cash and cash equivalents were $93.5 million as of December 31, 2020.
Net loss for the full year 2020 was $6.3 million, or $0.24 per share.
Net cash used in operations in full-year 2020 was $5.4 million.
The company remains on-track to initiate two pivotal Phase 3 studies in second half of 2021.